Table 1.
Characteristics of the Study Population, According to the Antibody Response After the Second Vaccine Dose
| Total Population (N = 69) | Anti-Spike Antibody Titer |
P | ||
|---|---|---|---|---|
| <50 AU/mL (n = 15) | ≥50 AU/mL (n = 54) | |||
| Clinical characteristics | ||||
| Age, y | 68.0 [53.0-76.0] | 75.0 [68.5-81.0] | 64.5 [49.3-76.0] | 0.006 |
| Male sex | 45 (65%) | 7 (47%) | 38 (70%) | 0.1 |
| Body mass index, kg/m2 | 26.6 [22.2-30.6] | 25.89 [21.5-30.1] | 27.0 [22.2-30.6] | 0.8 |
| Diabetes | 22 (32%) | 7 (47%) | 15 (28%) | 0.2 |
| History of hemopathy | 6 (9%) | 3 (20%) | 3 (6%) | 0.1 |
| History of immunosuppressive therapy | 9 (13%) | 8 (53%) | 1 (2%) | <0.001 |
| HD as dialysis modality | 38 (55%) | 7 (47%) | 31 (57%) | 0.6 |
| Dialysis vintage, y | 3.0 [1.0-6.0] | 2.0 [1.0-5.0] | 3.5 [1.0-6.0] | 0.4 |
| Kt/V | 1.6 [1.2-1.9] | 1.7 [1.4-1.9] | 1.50 [1.2-1.9] | 0.4 |
| Biological parameters | ||||
| Lymphocytes, ×109/L | 1.2 [0.9-1.6] | 1.0 [0.7-1.2] | 1.3 [1.0-1.7] | 0.03 |
| Neutrophilic polymorphonuclear cells, ×109/L | 3.9 [2.8-5.0] | 3.6 [2.9-4.4] | 4.1 [2.8-5.2] | 0.3 |
| Gamma globulin, g/L | 9.6 [7.5-12.7] | 7.0 [4.6-9.2] | 10.0 [8.3-13.9] | 0.001 |
| Serum albumin, g/dL | 3.7 [3.5-4.1] | 3.5 [3.3-3.9] | 3.8 [3.5-4.2] | 0.07 |
| Serum prealbumin, mg/dL | 34 [30-41] | 30 [25-35] | 35 [31-41] | 0.02 |
| C-reactive protein, mg/L | 2.2 [0.9-3.7] | 2.8 [1.2-4.0] | 2.2 [0.9-3.7] | 0.8 |
| Humoral response after 2nd dose | ||||
| Interval between 2nd dose and serology, d | 50 [31-58] | 56 [45-70] | 50 [30-56] | 0.1 |
| Anti-S1 Ab after 2nd dose, AU/mL | 284 [83-1,190] | 7 [3-32] | 485 [158-1,572] | <0.001 |
Results are shown as median [interquartile range] for continuous variables, or as number of patients (percentage) for categorical variables. Mann-Whitney test and Fisher exact test were used to compare continuous and categorical variables according to the dialysis modality. Abbreviations: Ab, antibody; AU, arbitrary unit; HD, hemodialysis; S1, spike protein S1.